Bristol kidney cancer drug cut death risk 37 pct in key patients

MADRID, Sept 10 (Reuters) – A combination of twoBristol-Myers Squibb immunotherapy drugs cut the risk ofdeath by 37 percent in a key group of kidney cancer patients,data from a closely watched clinical trial showed on Sunday.
The post Bristol kidney cancer drug cut death risk 37 pct in key patients appeared first on RocketNews | Top News Stories From Around the Globe.